Rebecca Spalding, a biotech reporter at Bloomberg News, has left the organization.
On Twitter, Spalding wrote, “I will have something new to say soon but for now, I’m reflecting fondly on the time I spent here and the wonderful colleagues I met here. I’m so proud to have started my journalism career at Bloomberg.”
Spalding was based on Boston. She has written about a drug with a $2 million price tag, a Harvard professor who made $400 million in an biotechnology IPO, Blackstone’s foray into drug development, and how Cambridge, Massachusetts, came to be a magnet for the industry.
She had been at Bloomberg for nearly four years and had previously interned at Forbes.
